Outcomes of limited stage primary bone diffuse large B-cell lymphoma in the rituximab era: a multicenter, retrospective study.

Autor:	Rezazadeh A; Medical College of Wisconsin., Szabo A; Medical College of Wisconsin., Khurana A; Mayo Clinic., Inwards DJ; Mayo Clinic., Lunning MA; University of Nebraska., Bartlett NL; Washington University., Caimi PF; Case Western., Rodgers TD; University of Rochester., Barr PM; University of Rochester., Chowdhury SM; Ohio State University., Epperla N; Ohio State University., Mendries H; Cleveland Clinic., Hill BT; Cleveland Clinic., Oh TS; Northwestern University., Karmali R; Northwestern University., Chang JE; University of Wisconsin-Madison., Goyal G; University of Alabama-Birmingham., Parsons BM; Gundersen Health System., Isaac KM; University of Virginia., Portell CA; University of Virginia., Monahan K; Medical College of Wisconsin., Siker M; Medical College of Wisconsin., King DM; Medical College of Wisconsin., Fenske TS; Medical College of Wisconsin. tfenske@mcw.edu.
Jazyk:	angličtina
Zdroj:	Haematologica [Haematologica] 2024 May 01; Vol. 109 (5), pp. 1439-1444. Date of Electronic Publication: 2024 May 01.
DOI:	10.3324/haematol.2023.283210
Abstrakt:	Primary bone diffuse large B-cell lymphoma is a rare variant of extranodal non-Hodgkin lymphoma historically treated with induction chemotherapy followed by consolidative radiation therapy (RT). It remains unknown whether RT confers additional benefit following rituximab-based chemoimmunotherapy (CIT) induction in patients with limited stage disease. We conducted a multicenter, retrospective analysis of patients treated between 2005 and 2019 using rituximab-based CIT regimens with or without consolidative RT to discern whether consolidative RT adds benefit in patients with stage I-II disease that could be encompassed in one radiation field. A total of 112 patients were included: 78 received CIT and radiation (RT group), and 34 received CIT alone (no RT group). The overall survival at 10 years was 77.9% in the RT group and 89.0% in the no RT group (P=0.42). The relapse-free survival at 10 years was 73.5% in the RT group and 80.3% in the no RT group (P=0.88). Neither improved overall survival nor relapse-free survival was associated with the addition of consolidative RT. Subgroup analysis of patients only achieving a partial response after CIT suggests that these patients may benefit from consolidative RT.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu